CTRI/2018/08/015399尚未招募未知
A multicenter, open label, randomized, balanced, two-treatment, single-period, multiple dose, parallel study to compare efficacy of Tiotropium Bromide inhalation spray, 2.5 mcg/puff of Dongguan HEC Pharm R&D Co., Ltd. with that of Spiriva® Respimat® (tiotropium bromide) spray, 2.5 mcg/puff of Boehringer Ingelheim Pharma GmbH & Co.KG in patient with chronic obstructive pulmonary disease (COPD). - 18-VIN-0329
Dongguan HEC Pharm RD Co Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Adult male or female patient of non-child-bearing potential or of childbearing potential but committed to consistent use of an acceptable method of birth control with age of >= 40 years.
- •2.Diagnosis of COPD, as defined by American Thoracic Society (ATS) [GOLD criteria].
- •3.Relatively stable airway obstruction with a post-bronchodilator FEV1 less than 80% of predicted normal and more than 30% of predicted normal, and post-bronchodilator FEV1 / FVC less than 70%
- •4.Current or former smokers (e.g., with history of more than or equal to 10 pack-years).
- •5.Patient with adequate bone marrow, renal and hepatic function as defined below:
- •Body system-Parameters Bone marrow functionANC more than or equal to 1500/mm3,
- •Platelet count more than or equal to 100,000/mm3
- •Hemoglobin more than or equal to 9 g/dL
- •Renal function
- •Serum creatinine less than or equal to 1.5 times ULN and creatinine clearance more than or equal to 51 to 80 mL/min [Cockroft and Gault]
- •Hepatic function
- •Bilirubin less than or equal to 1.5 times ULN,
- •ALT/AST less than or equal 5 times ULN
- •6.In PIâ??s opinion there is no overt safety concern with regard to two to four weeks of run-in period before first study dose to allow washout of prior COPD medications.
- •7.Patient willing and able to give written informed consent for participation in the study and comply with the study protocol.
- •8.No persistent clinically significant toxicities from prior medications at screening.
- •9.Females of child-bearing potential (FOCP) must agree to use an acceptable method of birth control such as sexual abstinence or at least 2 reliable modes of contraception, one of which must be a double-barrier method (e.g., condom with spermicidal gel or diaphragm with spermicidal gel) or IUD or vaginal spermicidal suppository from screening until the study completion.
- •Post-menopausal females defined as at least 12 consecutive months with no menses without an alternative medical cause
- •Surgically sterilized females with documented evidence of hysterectomy / bilateral salpingectomy / bilateral oophorectomy. Females without documented evidence of surgery and those who have undergone tubal ligation will be considered of child bearing potential.
排除标准
- •1.Known hypersensitivity or contraindication to tiotropium bromide or to any of the excipients or to atropine or its derivatives, e.g. ipratropium or oxitropium.
- •2.Known respiratory disorders other than COPD including, but not limited to the following: alpha-1 antitrypsin deficiency, cystic fibrosis, significant asthma, active bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, pulmonary edema, or interstitial lung disease.
- •3.History of paradoxical bronchospasm, narrow-angle glaucoma, prostatic hyperplasia, bladder neck obstruction, chronic constipation or any other condition, which, in the opinion of the investigator, would contraindicate the use of an anticholinergic agent.
- •4.Evidence or history of other clinically significant disease or abnormality (such as congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, stroke, glaucoma, or cardiac dysrhythmia), which, in the opinion of the investigator, would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbated during the study.
- •5.Known active tuberculosis
- •6.Patients with recent myocardial infarction within last 6 months or any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy in the past year; heart failure (NYHA Class III or IV) within the past year.
- •7.History of allergy or hypersensitivity to anticholinergic/muscarinic receptor antagonist agents, beta-2 adrenergic agonists, lactose/milk proteins, or specific intolerance to aerosolized tiotropium-containing products or known hypersensitivity to any of the proposed ingredients or components of the delivery system.
- •8.Hospitalization for COPD or pneumonia within 12 weeks prior to the initiation of the study.
- •9.Treatment for COPD exacerbation within 12 weeks prior to study.
- •10.Inability to discontinue COPD medications during the run-in and treatment periods.
- •11.Acute (viral or bacterial) upper or lower respiratory tract infection, sinusitis, rhinitis, pharyngitis, urinary tract infection or illness within 6 weeks prior to the initiation of the study.
- •12.Abnormal and significant electrocardiogram (ECG) finding prior to the screening, during the run-in and treatment periods.
- •13.Lung volume reduction surgery within 12 months prior to the initiation of the study
- •14.Chronic oxygen use for more than 12 hours/day.
- •15.Subject with positive human immunodeficiency virus (HIV) infection, a positive hepatitis screen including hepatitis B surface antigen, HCV and HAV antibodies.
- •16.Positive test results for urine drug scan or breath alcohol test at baseline
- •17.Subject with a history of difficulty in donating blood or difficulty in accessibility of veins.
- •18.Receipt of any Investigational Medicinal Product within the past 30 days of randomization or has less than 5 half-life from previous IMP receipt.
- •19.History of donation of blood/loss of blood (without replenishment) (1 unit or 350 ml) within 90 days prior to receiving the first dose of investigational medicinal product in the study.
研究者
相似试验
招募中
不适用
multicenter, open label, three periods, three sequence single dose bioequivalence study of Doxorubicin Injection in female patients with ovarian cancerCTRI/2021/03/032185ForDoz Pharma Corp
已完成
不适用
A multicenter, open label, randomized, balanced, two treatment, two period, twosequence, crossover, single dose, bioequivalence study of Docetaxel in patients with solid tumoursCTRI/2021/04/033049Zhuhai Beihai Biotech Co Ltd46
进行中（未招募）
不适用
To compare the blood levels of liposomal Doxorubicin (Sun Pharma) with Caelyx (Pegylated Liposomal doxorubicin) of Janssen-Cilag International NV in patients with ovary and breast cancerCTRI/2018/10/016089Sun Pharmaceutical Industries Ltd Vadodara India59
已完成
不适用
A bioequivalence study of Capecitabine tablets in adult human cancer patients.CTRI/2015/02/005514Shilpa Medicare Limited54
尚未招募
不适用
This is a comperative study of Capecitabine Capsule 500 mg tablets manufactured by sponsor with Xeloda 500 mg Tablets of Genetech USA, A Member of Roche group, USA, in adult patients with Breast cancer and Colorectal cancer under fed condition.CTRI/2012/04/002607Amneal Pharmaceuticals Ltd57